<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02302599</url>
  </required_header>
  <id_info>
    <org_study_id>CHIN-PLAGH-ST-003</org_study_id>
    <nct_id>NCT02302599</nct_id>
  </id_info>
  <brief_title>Mesenchymal Stem Cells to Treat Type II Diabetes</brief_title>
  <acronym>UC-MSCs</acronym>
  <official_title>Mesenchymal Stem Cell Infusion Therapy Between Efficacy and Safety of Chinese Type II Diabetic Subjects of Multicenter, Randomized, Double-blind, Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese PLA General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Between umbilical cord mesenchymal stem cells by the secretion characteristics, secrete a
      variety of cytokines and its immune inhibition, promoted the islet cell repair and
      regeneration, improve the state of high blood sugar in the body.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Between umbilical cord mesenchymal stem cells secrete a variety of cytokines, improve insulin
      target tissue insulin resistance, improve the body state of high blood sugar, reduce the
      metabolic disorder of islet progressive damage, ease or regeneration of the islet beta
      cells;Improve the micro environment, induced damage alpha cells into beta cells in the islet
      transformation, realize the islet beta cells in situ regeneration, reduce high blood
      sugar;Between mesenchymal stem cells have immunosuppressive effect, inhibition of T cell
      mediated immune response to beta cells, improve the micro environment of nutrition, promote
      islet cell repair and regeneration.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in MSCs Level From Baseline to Week 48 From Baseline</measure>
    <time_frame>48 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting Glucose Over Time</measure>
    <time_frame>48 weeks from baseline</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Response Rates for Reduction in Fasting Glucose of ≥20 mg/dl, a Reduction in HbA1c of ≥0.5%, and a Reduction in HbA1c of ≥0.8%</measure>
    <time_frame>48 weeks</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Type II Diabetes</condition>
  <arm_group>
    <arm_group_label>Umbilical cord mesenchymal stem cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive Umbilical cord mesenchymal stem cells in the absence of disease progression or unacceptable toxicity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controlled suspension liquid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive Controlled suspension liquid</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Umbilical cord mesenchymal stem cells</intervention_name>
    <description>Infusion treatment</description>
    <arm_group_label>Umbilical cord mesenchymal stem cells</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Controlled suspension liquid</intervention_name>
    <description>Infusion treatment</description>
    <arm_group_label>Controlled suspension liquid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Who signed the informed consent form ages of 20 and 60 years old or less or more men
             or women (not pregnancy).

          2. 24.0 kg/m2 or less BMI 40.0 kg/m2 or less

          3. Type 2 diabetes duration 15 years or less.

          4. Before the screening, joint or combined with insulin, oral medications to treat more
             than six months, HbA1c st13 of 7%, by the replacement for the door insulin 30 (total
             daily dose of 0.6 to 0.6 U/Kg) with metformin therapy 12 weeks, 7.0% ﹤ HbA1c of 12% or
             less of the subjects

          5. Based C peptide, p 1 ng/ml

        Exclusion Criteria:

          1. serious allergic constitution.

          2. according to the researcher's judgement, may endanger the safety of the subjects or
             solution compliance of any chronic disease or severe disease, including cancer, severe
             heart disease, kidney disease, liver disease, respiratory disease, nerve diseases of
             the nervous system, blood system diseases, etc.

          3. according to the local label, any contraindications to metformin.

          4. Stage IV above, diabetic nephropathy (excluding IV) and fertile diabetic retinopathy.

          5. People with mental illness, patients with drug and alcohol abuse.

          6. Within 1 month, used or are using the sugar metabolism of drugs, such as
             corticosteroids, thiazide diuretics, oral contraceptives, tricyclic antidepressants,
             and so on.

          7. Within 3 months, participated in any other clinical subjects

          8. Pregnancy or breast-feeding women, pregnant women, preparation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>weidong HAN</last_name>
    <role>Study Director</role>
    <affiliation>Chinese PLA General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>yiming MU</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese PLA General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Haojie HAO</last_name>
    <phone>+86(10)937917</phone>
    <email>haojieh@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chinese PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100039</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Haojie HAO</last_name>
      <phone>+86(10)937516</phone>
      <email>haojieh@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Hao H, Liu J, Shen J, Zhao Y, Liu H, Hou Q, Tong C, Ti D, Dong L, Cheng Y, Mu Y, Liu J, Fu X, Han W. Multiple intravenous infusions of bone marrow mesenchymal stem cells reverse hyperglycemia in experimental type 2 diabetes rats. Biochem Biophys Res Commun. 2013 Jul 5;436(3):418-23. doi: 10.1016/j.bbrc.2013.05.117. Epub 2013 Jun 11.</citation>
    <PMID>23770360</PMID>
  </reference>
  <reference>
    <citation>Wang XL, Lu JM, Pan CY, Mu YM, Dou JT, Ba JM. [Characteristics of the daily blood glucose profiles of impaired glucose tolerance and type 2 diabetes mellitus subjects by continuous glucose monitoring system]. Zhonghua Yi Xue Za Zhi. 2006 Mar 14;86(10):674-7. Chinese.</citation>
    <PMID>16681924</PMID>
  </reference>
  <reference>
    <citation>Si Y, Zhao Y, Hao H, Liu J, Guo Y, Mu Y, Shen J, Cheng Y, Fu X, Han W. Infusion of mesenchymal stem cells ameliorates hyperglycemia in type 2 diabetic rats: identification of a novel role in improving insulin sensitivity. Diabetes. 2012 Jun;61(6):1616-25. doi: 10.2337/db11-1141.</citation>
    <PMID>22618776</PMID>
  </reference>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 12, 2014</study_first_submitted>
  <study_first_submitted_qc>November 26, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 27, 2014</study_first_posted>
  <last_update_submitted>November 26, 2014</last_update_submitted>
  <last_update_submitted_qc>November 26, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 27, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese PLA General Hospital</investigator_affiliation>
    <investigator_full_name>Yiming Mu</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

